Description
Description
This page contains brief details about the drug eribulin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The FDA first approved Eribulin on November 15, 2010, for the treatment of patients with metastatic breast cancer. Later, on January 28, 2016, FDA approved this drug for the treatment of unresectable and metastatic liposarcoma.
Mechanism of Action of Eribulin
Eribulin stops the growth and spread of cancer cells, specifically targeting the growth phase of microtubules, which are structures that help cells divide. It prevents them from growing without interfering with their shrinking phase. Additionally, it causes tubulin, a protein essential for cell division, to clump together in a way that disrupts cell division. This ultimately leads to the blockage of the cell cycle (G2/M phase), disrupting the formation of structures necessary for cell division (mitotic spindles) and triggering cell death through apoptosis.
Uses of Eribulin
Eribulin was initially approved for metastatic (cancer that has spread to other parts of the body) or unresectable (cannot be removed with surgery) breast cancers not responding to anthracycline-based chemotherapy (a type of chemotherapy drug commonly used to treat various cancers). Recently, it gained FDA approval for liposarcoma treatment (a type of cancer originating from fat tissue), broadening its scope in addressing different types of cancer.
Eribulin Dosage available
Eribulin is administered solely by healthcare professionals through intravenous injections (injected directly into your veins), typically in a hospital or clinical setting. It is available in two strengths: 0.88mg and 0.5mg. Your doctor will determine the appropriate dosage for you based on factors such as your age and overall health condition.
